Cloxyquin (5-chloroquinolin-8-ol) is an activator of the two-pore domain potassium channel TRESK

Wright, P. D., Weir, G. , Cartland, J., Tickle, D., Kettleborough, C., Cader, M. Z. and Jerman, J. (2013) Cloxyquin (5-chloroquinolin-8-ol) is an activator of the two-pore domain potassium channel TRESK. Biochemical and Biophysical Research Communications, 441(2), pp. 463-468. (doi:10.1016/j.bbrc.2013.10.090) (PMID:24383077)

Full text not currently available from Enlighten.

Abstract

TRESK is a two-pore domain potassium channel. Loss of function mutations have been linked to typical migraine with aura and due to TRESK’s expression pattern and role in neuronal excitability it represents a promising therapeutic target. We developed a cell based assay using baculovirus transduced U20S cells to screen for activators of TRESK. Using a thallium flux system to measure TRESK channel activity we identified Cloxyquin as a novel activator. Cloxyquin was shown to have an EC50 of 3.8 μM in the thallium assay and displayed good selectivity against other potassium channels tested. Activity was confirmed using whole cell patch electrophysiology, with Cloxyquin causing a near two fold increase in outward current. The strategy presented here will be used to screen larger compound libraries with the aim of identifying novel chemical series which may be developed into new migraine prophylactics.

Item Type:Articles
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Weir, Dr Gregory
Authors: Wright, P. D., Weir, G., Cartland, J., Tickle, D., Kettleborough, C., Cader, M. Z., and Jerman, J.
College/School:College of Medical Veterinary and Life Sciences > Institute of Neuroscience and Psychology
Journal Name:Biochemical and Biophysical Research Communications
Publisher:Elsevier
ISSN:0006-291X
ISSN (Online):1090-2104
Published Online:25 October 2013

University Staff: Request a correction | Enlighten Editors: Update this record